News
The RET advocacy community grows with launch of...
RETpositive is excited to announce another key addition to the RET community: The Happy Lungs Project! We have had initial discussions about collaborating on RET specific medical research and other...
The RET advocacy community grows with launch of...
RETpositive is excited to announce another key addition to the RET community: The Happy Lungs Project! We have had initial discussions about collaborating on RET specific medical research and other...
Selpercatinib and Pralsetinib continue to make ...
Both of the recently FDA approved first generation, selective RET inhibitors Selpercatinib (Retevmo) and Pralsetinib (Gavreto) continued to garner attention at this years American Society of Clinical Oncology (ASCO) conference...
Selpercatinib and Pralsetinib continue to make ...
Both of the recently FDA approved first generation, selective RET inhibitors Selpercatinib (Retevmo) and Pralsetinib (Gavreto) continued to garner attention at this years American Society of Clinical Oncology (ASCO) conference...
Early results on another selective RET inhibito...
BOS172738 was already in trials since 2019 but we didn't know much about it. In the phase 1a results recently presented at ASCO 2021 they reported that their drug is...
Early results on another selective RET inhibito...
BOS172738 was already in trials since 2019 but we didn't know much about it. In the phase 1a results recently presented at ASCO 2021 they reported that their drug is...
Protein Degraders - New class of RET drugs in t...
Here we present new early-stage work being done on a completely new class of RET medications: protein degraders! This class has a lot of advantages over the current RET drugs:...
Protein Degraders - New class of RET drugs in t...
Here we present new early-stage work being done on a completely new class of RET medications: protein degraders! This class has a lot of advantages over the current RET drugs:...
No One Missed
Our partners at Lungevity have launched a campaign to promote comprehensive biomarker testing called No One Missed. This follows on our previous post on the importance of identifying genetic variants...
No One Missed
Our partners at Lungevity have launched a campaign to promote comprehensive biomarker testing called No One Missed. This follows on our previous post on the importance of identifying genetic variants...
Tissue Agnostic
More evidence that the future of cancer research is less about where cancer originates in the body and more about its biomarkers was presented by Vivek Subbiah, M.D., from MD...
Tissue Agnostic
More evidence that the future of cancer research is less about where cancer originates in the body and more about its biomarkers was presented by Vivek Subbiah, M.D., from MD...